Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.
Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, Petruželka L, Kumar S, Sanz-Moreno V, Brábek J. · 2017
Read Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. by Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, Petruželka L, Kumar S, Sanz-Moreno V, Brábek J. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5482322.txt.
Description
Gandalovičová and co-authors present a review in Trends in Cancer. They coin the term migrastatics for drugs that block cancer cell invasion and spread. In solid cancers, invasion and metastasis cause more than 90 percent of deaths. Yet standard drugs mainly target cell growth, not cell movement. No drug class targets spread itself, they argue.
The authors define actin polymerization and contractility as the key targets. They review candidate drugs, both natural products and synthetic compounds. Approval rules now demand tumor shrinkage, which can hide anti-spread effects. The authors call for rule changes and large-scale testing. Toxicity and clinical use get a frank closing review.
Catalog record
| CREATOR | Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, Petruželka L, Kumar S, Sanz-Moreno V, Brábek J. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |